Evidence map›Paper›PMID 27470028›Full record

ArticleThe lancet. HIV2016

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.

GBD 2015 HIV Collaborators

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in The lancet. HIV, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04735445 (IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in Patients With Human Immunodeficiency Virus), which is not on this map. Cited by 342 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
342citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04735445 naunknown statusnot on this mapstarted 2019, after this paper: background citation

IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in Patients With Human Immunodeficiency Virus (HIV) Infection

TypeinterventionalSponsorFelix GutierrezRan2019 to 2023Enrolled4,638ConditionsHIV/AIDS, CancerArmsDigital rectal exam and / or anal cytology (day 1 and after 36 months), Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy, Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months), Semestral cervical cytology and cervical sample for HPV detection, Appointment for mammography (day 1 and after 36 months)
3 · Its place in the literature

Who cites it

342 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Sex Worker Health Outcomes in High-Income Countries of Varied Regulatory Environments: A Systematic Review.International journal of environmental research and public health · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.Advances in nutrition (Bethesda, Md.) · 2020
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

282 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

GBD 2015 HIV Collaborators

Funding

University of Washington Center for Demography and Economics of Aging-OverallP30AG047845 · NIA · UNIVERSITY OF WASHINGTON · PI MURRAY, CHRISTOPHER J.L. · 2014 to 2019
$3.8M
Methodologies to Enhance Understanding of HIV-Associated Social DeterminantsR01MH110163 · NIMH · UNIVERSITY OF WASHINGTON · PI WANG, HAIDONG · 2016 to 2020
$1.9M
Development of Trumedicines Recognition Authentication Cloud Intelligence For Drug Product Surveillance (TRACI-4DPS) Software Solutions to Address FDA Post-Marketing Drug Surveillance ChallengesR43FD006302 · FDA · TRUMEDICINES, LLC · PI PROKOP, DAVID MICHAEL · 2018 to 2018
$225k
DBT-Wellcome Trust India AllianceDepartment of Health NIHR/CS/010/014Department of Health RP-PG-0407-10184FDA HHS R43 FD006302Medical Research Council MR/J002380/1NIA NIH HHS P30 AG047845NIMH NIH HHS R01 MH110163Wellcome Trust 099876Wellcome Trust 201900/Z/16/Z
6 · The paper itself

Abstract

backgroundTimely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy (ART), and mortality for 195 countries and territories from 1980 to 2015.

methodsFor countries without high-quality vital registration data, we estimated prevalence and incidence with data from antenatal care clinics and population-based seroprevalence surveys, and with assumptions by age and sex on initial CD4 distribution at infection, CD4 progression rates (probability of progression from higher to lower CD4 cell-count category), on and off antiretroviral therapy (ART) mortality, and mortality from all other causes. Our estimation strategy links the GBD 2015 assessment of all-cause mortality and estimation of incidence and prevalence so that for each draw from the uncertainty distribution all assumptions used in each step are internally consistent. We estimated incidence, prevalence, and death with GBD versions of the Estimation and Projection Package (EPP) and Spectrum software originally developed by the Joint United Nations Programme on HIV/AIDS (UNAIDS). We used an open-source version of EPP and recoded Spectrum for speed, and used updated assumptions from systematic reviews of the literature and GBD demographic data. For countries with high-quality vital registration data, we developed the cohort incidence bias adjustment model to estimate HIV incidence and prevalence largely from the number of deaths caused by HIV recorded in cause-of-death statistics. We corrected these statistics for garbage coding and HIV misclassification.

findingsGlobal HIV incidence reached its peak in 1997, at 3·3 million new infections (95% uncertainty interval [UI] 3·1-3·4 million). Annual incidence has stayed relatively constant at about 2·6 million per year (range 2·5-2·8 million) since 2005, after a period of fast decline between 1997 and 2005. The number of people living with HIV/AIDS has been steadily increasing and reached 38·8 million (95% UI 37·6-40·4 million) in 2015. At the same time, HIV/AIDS mortality has been declining at a steady pace, from a peak of 1·8 million deaths (95% UI 1·7-1·9 million) in 2005, to 1·2 million deaths (1·1-1·3 million) in 2015. We recorded substantial heterogeneity in the levels and trends of HIV/AIDS across countries. Although many countries have experienced decreases in HIV/AIDS mortality and in annual new infections, other countries have had slowdowns or increases in rates of change in annual new infections.

interpretationScale-up of ART and prevention of mother-to-child transmission has been one of the great successes of global health in the past two decades. However, in the past decade, progress in reducing new infections has been slow, development assistance for health devoted to HIV has stagnated, and resources for health in low-income countries have grown slowly. Achievement of the new ambitious goals for HIV enshrined in Sustainable Development Goal 3 and the 90-90-90 UNAIDS targets will be challenging, and will need continued efforts from governments and international agencies in the next 15 years to end AIDS by 2030.

fundingBill & Melinda Gates Foundation, and National Institute of Mental Health and National Institute on Aging, National Institutes of Health.

Indexed as

Global Burden of DiseaseGlobal HealthAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIV InfectionsHumansIncidencePrevalenceSeroepidemiologic StudiesTime FactorsYoung Adult

Identifiers

PMID27470028
PMCPMC5056319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.